South Korea to manage supply of non-essential drugs to prevent shortages

South Korea is taking proactive steps to ensure the stable supply of essential medicines, moving beyond the traditional designation of 'national essential drugs'. The Ministry of Food and Drug Safety (MFDS) has initiated regulatory amendments that will allow the government, pharmaceutical companies, and medical experts to collaboratively address potential supply chain vulnerabilities for a broader range of medications.

Under the proposed changes, drugs facing potential supply instability, even if not officially classified as national essential medicines, can be brought to the attention of the National Essential Medicines Stable Supply Council. This includes situations where manufacturers or importers report production or supply halts, or when medical professional groups request stable supply. The MFDS itself can also flag drugs if temporary demand surges or other factors threaten availability. This expanded scope reflects a growing awareness of the complexities in pharmaceutical supply chains and a commitment to patient welfare.

“

The government and industry, along with experts, will be able to discuss and prepare countermeasures for supply instability of medicines that are not designated as national essential medicines.

The Hankyoreh reports on this development, framing it as a crucial enhancement to public health infrastructure. While international coverage might focus on the regulatory details, the South Korean perspective emphasizes the government's commitment to safeguarding public health through a more robust and responsive system. This initiative is particularly significant in a country like South Korea, where rapid advancements in healthcare and an aging population place increasing demands on the pharmaceutical sector. By enabling early intervention and collaborative solutions, the government aims to prevent the kind of drug shortages that can have serious consequences for patient treatment and outcomes, reinforcing its role as a guardian of national health.

“

When a pharmaceutical company, importer, or seller reports a halt in production or import, or a shortage in production or import, or when medical professional groups request stable supply of medicines, or when the MFDS recognizes the need for stable supply due to temporary demand increase, etc., it will be subject to consultation by the National Essential Medicines Stable Supply Council.